Flavonoids and Reduction of Cardiovascular Disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD)

被引:10
|
作者
Russo, Patrizia [1 ]
Prinzi, Giulia [1 ]
Lamonaca, Palma [1 ]
Cardaci, Vittorio [2 ]
Fini, Massimo [3 ]
机构
[1] IRCCS San Raffaele Pisana, Unit Clin & Mol Epidemiol, Via Valcannuta 247, I-00166 Rome, Italy
[2] IRCCS San Raffaele Pisana, Unit Pulm Rehabil, Via Pisana 235, I-00163 Rome, Italy
[3] IRCCS San Raffaele Pisana, Sci Direct, Via Valcannuta 247, I-00166 Rome, Italy
关键词
Cardiovascular Disease Reduction; COPD; flavonoids; pathophysiological mechanisms; rehabilomics; inflammatory disease; comorbidity; CORONARY-HEART-DISEASE; ENDOTHELIAL FUNCTION; LIPID PROFILE; METAANALYSIS; COCOA; MANAGEMENT; RISK; MECHANISMS; CONSUMPTION; PREVALENCE;
D O I
10.2174/0929867325666180514100640
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Diseases (CV) Often Coexist. COPD and CVD are complex diseases characterized by a strict interaction between environment and genetic. The mechanisms linking these two diseases are complex, multifactorial and not entirely understood, influencing the therapeutic approach. COPD is characterized by several comorbidities, it hypothesized the treatment of cardiovascular co-morbidities that may reduce morbidity and mortality. Flavonoids are an important class of plant low molecular weight Secondary Metabolites (SMs). Convincing data from laboratory, epidemiological, and human clinical studies point the important effects on CVD risk prevention. Objective: This review aims to provide up-to-date information on the ability of Flavonoids to reduce the CVD risk. Conclusion: Current studies support the potential of Flavonoids to prevent the risk of CVD. Well-designed clinical studies are suggested to evaluate advantages and limits of Flavonoids for managing CVD comorbidity in COPD.
引用
收藏
页码:7048 / 7058
页数:11
相关论文
共 50 条
  • [31] PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN OUTPATIENTS WITH CARDIOVASCULAR DISEASES IN JAPAN
    Onishi, Katsuya
    Yoshimoto, Daisuke
    Hagan, Gerry
    Jones, Paul W.
    [J]. RESPIROLOGY, 2013, 18 : 183 - 183
  • [32] Cardiovascular morbidity and mortality among persons with chronic obstructive pulmonary disease(COPD)
    de Luise, C
    Lanes, SF
    Sidney, S
    Quesenberry, CP
    Eisner, M
    [J]. CHEST, 2004, 126 (04) : 739S - 739S
  • [33] Burden of Cardiovascular Disease in Chronic Obstructive Pulmonary Disease
    Agarwal, Shikhar
    Rokadia, Haala
    Senn, Todd
    Menon, Venu
    [J]. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2014, 47 (02) : 105 - 114
  • [34] Chronic Obstructive Pulmonary Disease Plus (COPD plus )® as a Friendly App for Patients with Chronic Obstructive Pulmonary Disease
    Guimaraes, V. A.
    Correa, K. S.
    Rabahi, M. F.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [35] Chronic obstructive pulmonary disease and cardiovascular risk
    Alonso, JLI
    Arroyo-Espliguero, R
    [J]. ARCHIVOS DE BRONCONEUMOLOGIA, 2005, 41 (08): : 410 - 412
  • [36] Chronic obstructive pulmonary disease and cardiovascular events
    Villar Alvarez, Felipe
    de Miguel Diez, Javier
    Alvarez-Sala, Jose Luis
    [J]. ARCHIVOS DE BRONCONEUMOLOGIA, 2008, 44 (03): : 152 - 159
  • [37] Cardiovascular Risk in Chronic Obstructive Pulmonary Disease
    Ninomiya, Toshiharu
    [J]. CIRCULATION JOURNAL, 2014, 78 (09) : 2164 - 2165
  • [38] Chronic obstructive pulmonary disease and cardiovascular system
    Gurgun, Alev
    Gurgun, Cemil
    [J]. TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2008, 56 (04): : 464 - 471
  • [39] CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CARDIOVASCULAR COMORBIDITY
    Aisanov, Z. R.
    Chuchalin, A. G.
    Kalmanova, E. N.
    [J]. KARDIOLOGIYA, 2019, 59 (08) : 24 - 36
  • [40] Cardiovascular risk in chronic obstructive pulmonary disease
    Maclay, John D.
    McAllister, David A.
    MacNee, William
    [J]. RESPIROLOGY, 2007, 12 (05) : 634 - 641